EXICURE, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EXICURE, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $1.00K.
- EXICURE, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $546.00K.
- EXICURE, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $19.00K.
- EXICURE, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-06-30 was $50.00K, a 194.12% increase year-over-year.
- EXICURE, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- EXICURE, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $546.00K, a 48.77% increase from fiscal 2020.
- EXICURE, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $367.00K, a 389.33% increase from fiscal 2019.
- EXICURE, INC. stock issued during period, value, stock options exercised for fiscal 2019 was $75.00K, a 82.93% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-27 | |
| 2022-06-30 | $1.00K 10-Q/A · filed 2024-06-06 | |
| 2021-12-31 | $546.00K 10-K · filed 2023-03-27 | |
| 2021-03-31 | $546.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $367.00K 10-K · filed 2022-03-25 | |
| 2020-09-30 | $19.00K 10-Q · filed 2021-11-19 | |
| 2020-06-30 | $50.00K 10-Q · filed 2021-11-19 | |
| 2019-12-31 | $75.00K 10-K · filed 2021-03-11 | |
| 2019-06-30 | $17.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $41.00K 10-K · filed 2020-03-10 |
| 2018-09-30 | $34.00K 10-Q · filed 2019-11-07 | $41.00K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | |
| 2018-03-31 | $7.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $43.00K 10-K/A · filed 2019-09-23 |
| 2016-12-31 | $33.00K 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |